Key terms
About AXGN
Axogen, Inc. engages in the development and market of surgical solutions for peripheral nerve regeneration and repair. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. The firm’s products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest AXGN news
Mar 07
1:01am ET
New Accounting & Financial Operations Risk for AxoGen – What’s the Latest?
Mar 06
11:17pm ET
Axogen’s Strong Growth Prospects and Positive Analyst Outlook Prompt Buy Rating and Increased Price Target
Mar 06
8:54am ET
AxoGen files $100M mixed securities shelf
Mar 06
12:35am ET
Buy Rating Affirmed: AxoGen’s Robust Growth and Market Potential Drive Positive Outlook
Mar 05
4:43pm ET
AxoGen Releases Updated Corporate Presentation Online
Mar 05
7:32am ET
AxoGen Unveils Q4 and Full Year 2023 Financial Results
Mar 05
7:12am ET
AxoGen sees FY24 revenue $177M-$181M, consensus $178.85M
Mar 05
7:11am ET
AxoGen reports Q4 adjusted EPS (6c), consensus (10c)
Jan 22
3:17pm ET
Buy Rating Affirmed for AxoGen on Strong Clinical Results and Encouraging Sales Performance
Jan 18
5:01pm ET
AxoGen announces results from REPOSE clinical study
Jan 09
1:10am ET
Analysts Offer Insights on Healthcare Companies: scPharmaceuticals (SCPH), Alnylam Pharma (ALNY) and AxoGen (AXGN)
Jan 05
10:46am ET
Buy Rating Affirmed for AxoGen on Strong Growth and Promising Market Prospects
Jan 04
4:49pm ET
AxoGen raises 2023 revenue view to upper end of $154M-$159M view
Jan 04
4:48pm ET
AxoGen sees Q4 revenue $42.7M, consensus $40.68M
Jan 04
4:41pm ET
AxoGen CEO Karen Zaderej to retire from company by January 2025
No recent press releases are available for AXGN
AXGN Financials
Key terms
Ad Feedback
AXGN Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
AXGN Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range